Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With ERBB Receptor Deregulation.

Trial Profile

Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With ERBB Receptor Deregulation.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2018

At a glance

  • Drugs Afatinib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms LUX-Bladder 1
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 10 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium
    • 10 Feb 2018 The trial commenced in June 2016; as of October 4, 2017, 201 samples have been analyzed, with 24.3% and 8% of pts with genetic alterations potentially eligible for inclusion in Cohort A and B, respectively. date, 12 pts have received study treatment in Cohort A and 6 in Cohort B; recruitment is ongoing as per trial design presented at the 2018 Genitourinary Cancers Symposium
    • 21 Dec 2017 Planned End Date changed from 29 Mar 2019 to 30 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top